Know Cancer

forgot password

Single Agent Phase II Study of Forodesine (BCX1777) in the Treatment of Cutaneous T-Cell Lymphoma

Phase 2
18 Years
Not Enrolling
Cutaneous T-cell Lymphoma (CTCL),

Thank you

Trial Information

Single Agent Phase II Study of Forodesine (BCX1777) in the Treatment of Cutaneous T-Cell Lymphoma

Inclusion Criteria:

- Males or non-pregnant females aged ≥18 years;

- Histologically confirmed diagnosis of CTCL, including mycosis fungoides and/or Sezary
syndrome, documentation of diagnosis by histologic examination should be available;

- Subjects with CTCL stages IB, IIA, IIB, III, or IVA at the screening visit (i.e.
stage refers to stage at study entry) and who have persistent, progressive, or
recurrent disease during or following treatment with at least three forms of systemic
therapy, one of which must have been oral bexarotene, unless treatment with oral
bexarotene was not tolerated or was medically contraindicated;

- Anticipated life expectancy greater than 6 months;

- Performance status of 0, 1, or 2 by Eastern Cooperative Oncology Group (ECOG)

- Females of childbearing potential must have a negative serum pregnancy test within 14
days prior to initiation of study treatment;

- Females of childbearing potential and sexually active males, if indicated, must be
willing and able to use method(s) of contraception that are adequate to prevent or
minimize the risk of pregnancy for the duration of the study;

- Written informed consent to participate in the study.

Exclusion Criteria:

- Proven or suspected extracutaneous visceral CTCL involvement (M1) (CTCL stage IVB)
(note: presence of lymphadenopathy is permitted);

- Previous treatment with Forodesine;

- ECOG performance status >2;

- Concomitant use of any anti-cancer therapy or immune modifier;

- Concomitant use of any investigational agent or device;

- Concurrent treatment with any other anti-CTCL therapy, or radiation therapy [topical
corticosteroids (classes 1 and 2 prohibited) or low dose oral corticosteroids (≤10
mg/day prednisone or equivalent) will not be excluded, but if used, must be a stable
dose and schedule during the four weeks immediately prior to study entry];

- Use of previous therapies for CTCL within the timeframes specified below:

1. Phototherapy in the previous 30 days;

2. Electron beam therapy, photopheresis, systemic anticancer therapy, interferon
therapy, or other investigational therapy in the previous 30 days;

3. Oral retinoid (including bexarotene) in the previous 30 days

4. Alemtuzumab (Campath) or other monoclonal antibody within the previous 30 days

5. Vorinostat or other HDAC inhibitor within previous 30 days

6. Any investigational therapy within the previous 30 days;

- ALT or AST >3 times ULN or alkaline phosphatase >2 times ULN;

- Calculated creatinine clearance ≤50 mL/min or serum creatinine ≥1.8 mg/dL;

- Serum potassium <3.3 mg/dL or >5.5 mg/dL;

- Evidence of clinically significant (uncontrolled) hypo- or hyperthyroidism;

- Recent (in past 6 months) medically significant cardiac event (i.e., myocardial
infarction, cardiac surgery);

- Presence of congestive heart failure (NYHA class IV) or angina (NYHA class IV) or
presence of a medically significant dysrhythmia;

- Presence of any of the following ECG findings:

1. Congenital long QT syndrome;

2. QTc interval >480 msec (Bazett's correction);

- Presence of uncontrolled hypertension manifested by systolic blood pressure ≥160 mmHg
and/or diastolic blood pressure ≥90 mmHg;

- Hemoglobin <9.0 gm/dL (intermittent red blood cell transfusions permitted);

- Absolute neutrophil count <1500 cells/mm3;

- Platelet count <75,000/mm3;

- Requirement for neutrophil or platelet growth factor therapy or administration of
such therapy in the previous 30 days;

- CD4 count <200/mm3;

- Documented current active infection with HIV, Hepatitis B, Hepatitis C, and/or CMV;

- Presence of uncontrolled bacterial or viral infection (subject may be receiving
chronic antimicrobial therapy); or,

- History of culture-documented bacteremia in the previous 2 weeks;

- Recent (i.e., in past 2 weeks) change in doses or regimens of medications used for
any chronic non-oncologic condition for reasons of worsening of the chronic illness
(change in doses of chronic medications associated with improvement in a chronic
illness are not exclusionary);

- Presence of any acute or chronic non-oncologic disease which, in the opinion of the
investigator, is medically uncontrolled;

- Coexistent second malignancy or history of prior malignancy within previous 5 years
[excluding basal cell or squamous cell carcinoma of skin and cervical neoplasia
(carcinoma-in-situ) that has been treated curatively]. Surgically resected
nonmelanomatous skin cancer (non-CTCL) with no evidence of recurrence in previous 6
months is permitted; and,

- Any significant medical or psychiatric condition that, in the opinion of the
investigator, might prevent the subject from complying with all required study

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The primary objective of this study is to determine the objective response rate to treatment with oral forodesine in subjects with cutaneous manifestations of CTCL subjects, stages IIB, III, and IVA.

Outcome Time Frame:

Duration of Study

Safety Issue:


Principal Investigator

Nashat Gabrail, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Gabrail Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

July 2007

Completion Date:

December 2011

Related Keywords:

  • Cutaneous T-cell Lymphoma (CTCL),
  • T-Cell
  • Lymphoma
  • Forodesine
  • Mycosis Fungoides
  • Lymphoma
  • Lymphoma, T-Cell
  • Lymphoma, T-Cell, Cutaneous



Stanford University Medical Center Stanford, California  94305-5408
Washington University School of Medicine Saint Louis, Missouri  63110
Boston Medical Center Boston, Massachusetts  02118
Yale Cancer Center New Haven, Connecticut  06520-8028
Seattle Cancer Care Alliance Seattle, Washington  98109
Duke University Medical Center Durham, North Carolina  27710
Emory University Atlanta, Georgia  30322
Gabrail Cancer Center Canton, Ohio  44718
Moffitt Cancer Center Tampa, Florida  33612
Upstate Medical University Syracuse, New York  13210
LSU Health Sciences Center, Feist-Weiller Cancer Center Shreveport, Louisiana  71130
University of Alabama at Birmingham, Comprehensive Cancer Ctr Birmingham, Alabama  35294-3300
Hackensack University Medical Ctr Hackensack, New Jersey  07601
Wake Forest University Health Sceinces, Dept. of Dermatology Winston-Salem, North Carolina  27157
University Hospitals Case Medical Center, Dept. of Dermatology Cleveland, Ohio  44106
Hospital at the University of Pennsylvania Philadelphia, Pennsylvania  19104
Hillman Cancer Ctr., University of Pittsburgh Pittsburgh, Pennsylvania  15213
M.D. Anderson Cancer Center - Dermatology Houston, Texas  77030
University of Wisconsin-Madison, Dept of Dermatology Madison, Wisconsin  53715